B&W presents FASILIS and IN2LifeSciences at the ShareBiotech event
At the second public event of ShareBiotech, titled Fostering Open Innovation in Biotechnology: New approaches in biopharmaceutical delivery and building networks in biotechnology, Anneke Stolk presented the effectiveness of vouchers as a brokering and networking tool. Approximately 150 people have visited the event in Pamplona, Spain.
The objective of ShareBiotech is to strengthen the biotechnology sector within the Atlantic Area as well as to improve the service offer of the technological core facilities involved. ShareBiotech notably aims at making the access to technological core facilities easier for companies, in particular SMEs, working in the fields of human health, nutrition, agriculture/food-processing, cosmetics, marine biology and environment. ?
FASILIS, short for Facility Sharing in Life Sciences, gives SMEs access to a far wider range of research facilities than is currently available at a regional level, broadening their competence network. In FASILIS, vouchers are used as incentives for Life Science SMEs to transnationally collaborate with public and private research facilities, stimulating innovation and new business development. Regional Contact Points are a first point of contact for both SMEs and facilities. Together, the Regional Contact Points in the 6 life science regions act as an international matchmaking network. 67 SMEs were matched to 51 state of the art facilities.
Last April, the 8 leading Life Science regions involved, kicked off IN2LifeSciences (Transnational Innovation Incentives for Life Science SMEs). IN2LifeSciences capitalises on the results of FASILIS and helps SMEs to tackle specific bottlenecks, which SMEs encounter in bringing research to the market. These bottlenecks may be market-related, technology related or related to financing. The partners will bring SMEs in contact with relevant entities from other regions, using various brokering tools and a joint fund for incentives to initiate durable relationships. The first financial event in which IN2LifeSciences will be involved
Published @ May 24, 2012 by Anneke Stolk